Sanofi cell-based flu vaccine enters clinic
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi-Aventis' vaccines division has initiated the first clinical trial of its cell culture-based influenza vaccine. The 100-person U.S. trial is part of a contract awarded by HHS to accelerate development of a new cell culture-based influenza vaccine, Sanofi noted. Novartis is another firm with a cell-based flu vaccine in development; the firm acquired the vaccine through its purchase of Chiron...